Storia in 7 fonti

Does Revolution Medicines' pancreatic cancer drug have even greater potential?

Revolution Medicines' pancreatic cancer drug has not yet been approved — and already talk has shifted to how (and when) its use might be expanded.

Raccontata daeu.usatoday.comnewscientist.comhindustantimes.compharmaceutical-technology.comstartmag.itscientificamerican.comstatnews.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo1 g fa

Does Revolution Medicines' pancreatic cancer drug have even greater potential?

Revolution Medicines' pancreatic cancer drug has not yet been approved — and already talk has shifted to how (and when) its use might be expanded.

originale

pharmaceutical-technology.com3 g fa

ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer - Pharmaceutical Technology

The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.

Leggi questa versione → originale

hindustantimes.com3 g fa

Revolution Medicines' new cancer pill extends life: ‘Molecular glue’ works, study shows

Revolution Medicines' daraxonrasib extends median survival to 13.2 months in pancreatic cancer via a molecular glue approach targeting RAS mutations. For biotech strategists and tech leaders, the molecular glue approach demonstrates advances in structure-based drug design, opening new R&D paradigms in precision medicine.

Leggi questa versione → originale

startmag.it2 g fa

Tumore al pancreas, perché il farmaco di Revolution Medicines è rivoluzionario - Startmag

Daraxonrasib (Revolution Medicines) ha quasi raddoppiato la sopravvivenza mediana nel tumore pancreatico: 13,2 mesi vs 6,7 mesi, con riduzione mortalità del 60%. Primo inibitore RAS(ON) efficace su KRAS; sblocca classe considerata impossibile, estendibile a polmone e colon-retto oltre pancreas.

Leggi questa versione → originale

eu.usatoday.com3 g fa

Pancreatic cancer 'miracle' drug daraxonrasib doubles survival rate in new trial

The drug daraxonrasib nearly doubled the overall survival rates of pancreatic cancer patients. Here's how it works and who can get it.

Leggi questa versione → originale

scientificamerican.com1 g fa

Landmark pancreatic cancer treatment paves way for targeting other tricky tumors

Unprecedented results against a stubbornly hard-to-treat cancer are boosting optimism that other challenging tumors will be next

Leggi questa versione → originale

Timeline cronologica

1. lunedì 1 giugno 2026·eu.usatoday.com
   

   Pancreatic cancer 'miracle' drug daraxonrasib doubles survival rate in new trial

   The drug daraxonrasib nearly doubled the overall survival rates of pancreatic cancer patients. Here's how it works and who can get it.

2. lunedì 1 giugno 2026·newscientist.com
   

   'Transformative' pancreatic cancer drug doubles survival time

   People with advanced pancreatic cancer taking an experimental daily pill lived nearly twice as long as those receiving chemotherapy infusions

3. lunedì 1 giugno 2026·hindustantimes.com
   

   Revolution Medicines' new cancer pill extends life: ‘Molecular glue’ works, study shows

   While the drug is not a cure, researchers say it could meaningfully improve both the length and quality of life for patients with advanced disease. | World News

4. lunedì 1 giugno 2026·pharmaceutical-technology.com
   

   ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer - Pharmaceutical Technology

   The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.

5. martedì 2 giugno 2026·hindustantimes.com
   

   Scientifically Speaking: A pill takes on pancreatic cancer

   For decades, the molecular switch that drives most pancreatic cancers was ‘undruggable’. No longer. A new drug has now nearly doubled how long patients live.

6. mercoledì 3 giugno 2026·startmag.it
   

   Tumore al pancreas, perché il farmaco di Revolution Medicines è rivoluzionario - Startmag

   La presentazione dei risultati di daraxonrasib, una pillola sperimentale che nel tumore del pancreas metastatico ha quasi raddoppiato la

7. mercoledì 3 giugno 2026·scientificamerican.com
   

   Landmark pancreatic cancer treatment paves way for targeting other tricky tumors

   Unprecedented results against a stubbornly hard-to-treat cancer are boosting optimism that other challenging tumors will be next

8. giovedì 4 giugno 2026·statnews.com
   

   Does Revolution Medicines' pancreatic cancer drug have even greater potential?

   Revolution Medicines' pancreatic cancer drug has not yet been approved — and already talk has shifted to how (and when) its use might be expanded.